Search results for " Cohort Studies"

showing 10 items of 130 documents

Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score

2021

The British journal of surgery 108(11), 1274-1292 (2021). doi:10.1093/bjs/znab183

Cuidado perioperatorioAcademicSubjects/MED00910Settore MED/18 - CHIRURGIA GENERALEMedizinpulmonary complicationspreoperative screeningDatasets as TopicSurgical Procedures Operative/mortality030230 surgeryperioperative care ; surgical procedures ; operative mortality ; machine learning ; sars-cov-2Medical and Health SciencesProcediments quirúrgicsCohort StudiesMachine LearningTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineModelsProcedimientos quirúrgicosMedicine and Health SciencesCOVIDSurg Collaborative Co-authorsMedicine030212 general & internal medicineskin and connective tissue diseasesRapid Research Communication11 Medical and Health SciencesOperative/mortalitySARS-CoV-19COVID-19/mortalityStatisticalCOVID-19/mortality; Cohort Studies; Datasets as Topic; Humans; Machine Learning; Models Statistical; Risk Assessment; SARS-CoV-2; Surgical Procedures Operative/mortalityCOVID-19; Cohort Studies; Datasets as Topic; Humans; Machine Learning; SARS-CoV-2; Surgical Procedures Operative; Models Statistical; Risk AssessmentAprendizaje automáticoOperativeSurgical Procedures OperativeoutcomeOperativo[SDV.IB]Life Sciences [q-bio]/BioengineeringPatient SafetyAcademicSubjects/MED000106.4 SurgeryLife Sciences & BiomedicineHuman61medicine.medical_specialty616.9Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-.Risk AssessmentNOCOVIDSurg CollaborativeVaccine Related03 medical and health sciencesClinical ResearchBiodefenseCures perioperatòriesAprenentatge automàticMortalitatHumansOperatiusLS7_4Surgical ProceduresScience & TechnologyModels Statisticalbusiness.industrySARS-CoV-2SARS-CoV-2 infectionKirurgiPreventionnot indicatedcovid 19fungiEvaluation of treatments and therapeutic interventionsCOVID-19Perioperativecovid 19; pulmonary complications; postoperative mortality risk; SARS-CoV-2 infection; preoperative screening; vaccinationvaccinationmortalityGood Health and Well BeingMortalidadEmergency medicineSurgeryHuman medicineCohort Studiebusinesspostoperative mortality riskPerioperative care
researchProduct

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults

2015

Objective: The prevalence of overweight and obesity is increasing among HIV-infected patients. Whether standard antiretroviral drug dosage is adequate in heavy individuals remains unresolved. We assessed the virological and immunological responses to initial efavirenz (EFV)-containing regimens in heavy compared to normal-weight HIV-infected patients. Design: Observational European cohort collaboration study. Methods: Eligible patients were antiretroviral-naive with documented weight prior to EFV start and follow-up viral loads after treatment initiation. Cox regression analyses evaluated the association between weight and time to first undetectable viral load ( 50 copies/ml) after initial s…

CyclopropanesMaleEfavirenz; HIV; Immunological response; Virological response; Weight; Adult; Antiretroviral Therapy Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Obesity; Regression Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Body WeightHIV InfectionsOverweight10234 Clinic for Infectious DiseasesCohort Studieschemistry.chemical_compoundAntiretroviral Therapy Highly ActiveImmunology and AllergyHIV InfectionImmunological responsevirus diseasesVirological responseMiddle AgedViral LoadReverse Transcriptase InhibitorTreatment OutcomeInfectious DiseasesAlkynesCohort2723 Immunology and AllergyRegression AnalysisReverse Transcriptase InhibitorsFemalemedicine.symptomViral loadCohort studyHumanBenzoxazineAdultmedicine.medical_specialtyEfavirenzImmunologyAntiretroviral Therapy610 Medicine & healthRegression AnalysiPharmacokineticsInternal medicinemedicineHumansHighly ActiveObesity2403 Immunologybusiness.industryProportional hazards modelBody WeightHIV2725 Infectious DiseasesEfavirenz; HIV; Immunological response; Virological response; Weight; Adult; Antiretroviral Therapy Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Obesity; Regression Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Body Weight; Immunology and Allergy; Immunology; Infectious Diseasesmedicine.diseaseWeightObesityBenzoxazinesCD4 Lymphocyte Countlnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]chemistryImmunologyCohort StudieEfavirenzbusiness
researchProduct

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir i…

2013

Objectives: To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients. Patients and methods: A retrospective, longitudinal, multicentre analysis of adult patients enrolled in the Antiretroviral Resistance Cohort Analysis (ARCA), a national prospective observational cohort of HIV-1-infected patients followed up at more than 100 clinical and laboratory units in Italy. Patients eligible were those starting first-line antiretroviral therapy between 1 June 2004 and 15 April 2011 and who were followed up for at least 6 months. The primary endpoint was durability, define…

CyclopropanesTime FactorsPyridinesPyridineDrug ResistanceLopinavir/ritonavirLongitudinal StudieHIV InfectionsPharmacologyAntiviral therapyDeoxycytidineLopinavirCohort Studieschemistry.chemical_compoundimmune system diseasesRetrospective StudieOrganophosphonateMedicineEmtricitabineHIV InfectionPharmacology (medical)ViralLongitudinal StudiesProspective StudiesProspective cohort studyvirus diseasesLopinavirInfectious DiseasesAnti-Retroviral AgentsItalyAlkynesCombinationOligopeptideHIV/AIDSDrug Therapy CombinationOligopeptidesmedicine.drugHumanMicrobiology (medical)Benzoxazinemedicine.medical_specialtyEfavirenzTime Factorantiretroviral therapyAtazanavir SulfateOrganophosphonatesfirst-line therapy tenofovir emtricitabine atazanavir/ritonavirSettore MED/17 - MALATTIE INFETTIVEEmtricitabineDurabilityDrug TherapyInternal medicineDrug Resistance ViralDrug utilizationHumansAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Time Factors; Pharmacology; Pharmacology (medical); Infectious DiseasesTenofovirRetrospective StudiesAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time FactorsPharmacologyRitonavirbusiness.industryAdenineAtazanavirBenzoxazinesRegimenProspective StudiechemistryHIV-1RitonavirAnti-Retroviral AgentCohort StudieTenofovir/emtricitabinebusiness
researchProduct

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohor…

2015

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the i…

Genetics and Molecular Biology (all)MaleChronic HepatitisHepacivirusRibavirin/adverse effectsAsthenia/chemically inducedHepacivirusPolyethylene GlycolBiochemistryPolyethylene GlycolsBody Mass IndexChronic Liver Disease0302 clinical medicineNeutropenia/chemically inducedInterferon-alpha/adverse effectsMedicineChroniclcsh:ScienceLiver Diseasesvirus diseasesAntiviral Agents/adverse effectsCohortScience & Technology - Other Topics030211 gastroenterology & hepatologyDrug Therapy CombinationCohort studyHumanmedicine.medical_specialtyAlpha interferonGastroenterology and HepatologyAntiviral AgentsMicrobiologyDose-Response Relationship03 medical and health sciencesPharmacotherapyHepatitis C Chronic/drug therapyDose Prediction MethodsDrug TherapyAnemia/chemically inducedHumansHemoglobinAgedMedicine and health sciencesBiochemistry Genetics and Molecular Biology (all)HepaciviruScience & TechnologyDose-Response Relationship DrugFlaviviruseslcsh:ROrganismsBiology and Life SciencesProteinsmedicine.diseasedigestive system diseaseschemistryAgricultural and Biological Sciences (all)Withholding TreatmentAstheniaImmunologyProportional Hazards Modellcsh:QHuman medicineRNA virusesPhysiologylcsh:MedicinePeginterferon-alfaPolyethylene Glycols/adverse effectsAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)Cohort Studieschemistry.chemical_compoundOutcome Assessment Health CareMedicine and Health Sciences030212 general & internal medicineViralPathology and laboratory medicineMultidisciplinarybiologyHepatitis C virusPharmaceuticsMedicine (all)AnemiaHepatitis CHematologyRecombinant ProteinOutcome Assessment (Health Care)/methodsMiddle AgedMedical microbiologyHepatitis CRecombinant ProteinsHost-Pathogen InteractionMultidisciplinary SciencesPhysiological ParametersResearch DesignCombinationHost-Pathogen InteractionsVirusesRNA ViralFemaleDrugPathogensHost-Pathogen Interactions/drug effectsResearch ArticleAdultNeutropeniaClinical Research DesignResearch and Analysis MethodsOutcome Assessment (Health Care)Internal medicineRibavirinRecombinant Proteins/adverse effectsRNA Viral/bloodAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding TreatmentAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Medicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Proportional Hazards ModelsAntiviral Agentbusiness.industryRibavirinBody WeightHepacivirus/drug effectsViral pathogensInterferon-alphaHepatitis C Chronicbiology.organism_classificationHepatitis virusesMicrobial pathogensRNAAdverse EventsCohort StudiebusinessPloS one
researchProduct

Combined associations of body weight and lifestyle factors with all cause and cause specific mortality in men and women: prospective cohort study

2016

Objective  To evaluate the combined associations of diet, physical activity, moderate alcohol consumption, and smoking with body weight on risk of all cause and cause specific mortality. Design  Longitudinal study with up to 32 years of follow-up. Setting  Nurses’ Health Study (1980-2012) and Health Professionals Follow-up Study (1986-2012). Participants  74 582 women from the Nurses’ Health Study and 39 284 men from the Health Professionals Follow-up Study who were free from cardiovascular disease and cancer at baseline. Main outcome measures  Exposures included body mass index (BMI), score on the alternate healthy eating index, level of physical activity, smoking habits, and alcohol drink…

GerontologyAdultMaleStatistics as TopicDisease030204 cardiovascular system & hematologyLower riskBody Mass IndexCohort Studies03 medical and health sciences0302 clinical medicineSex FactorsBiasEnvironmental healthNeoplasmsCause of DeathDiabetes MellitusMedicineHealth Status IndicatorsHumans030212 general & internal medicineLongitudinal StudiesProspective StudiesProspective cohort studyf body weightLife StyleCause of deathAged2. Zero hungerbusiness.industryResearchHazard ratioBody WeightAdult; Aged; Bias (Epidemiology); Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus Type 2; Female; Health Status Indicators; Health Surveys; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasms; Prospective Studies; Sex Factors; Statistics as Topic; United States; Body Weight; Cause of Death; Life Stylelifestyle factorsGeneral MedicineMiddle AgedHealth SurveysConfidence intervalUnited States3. Good healthDiabetes Mellitus Type 2Cardiovascular DiseasesBias (Epidemiology)FemalebusinessBody mass indexType 2Cohort study
researchProduct

Multidimensional Frailty Predicts Mortality Better than Physical Frailty in Community-Dwelling Older People: A Five-Year Longitudinal Cohort Study

2021

Frailty is a common syndrome in older people that carries an increased risk of mortality. Two main models describe frailty, either as a loss of physical functions or as an accumulation of multiple deficits. The aim of our study was to compare the physical frailty index developed in the Cardiovascular Health Study (CHS) with a multidimensional frailty tool, the Multidimensional Prognostic Index (MPI), in predicting death in community-dwelling older subjects. Four hundred and seven community-dwelling older subjects were enrolled. Each subject underwent a comprehensive geriatric assessment (CGA) with calculation of the MPI and CHS index. Mortality was recorded over the following 5 years. In th…

GerontologyMaleHealth Toxicology and MutagenesisCardiovascular healthFrail ElderlyFrailty IndexArticleCohort StudiesMedicineHumansLongitudinal StudiesLongitudinal cohortGeriatric AssessmentAgedAged 80 and overFrailtybusiness.industrySignificant differencePublic Health Environmental and Occupational HealthRMean ageGeriatric assessmentmortalityFrailty Mortality Multidimensional prognostic index Prognosis Aged Aged 80 and over Cohort Studies Female Frail Elderly Geriatric Assessment Humans Independent Living Longitudinal Studies Male Frailtymultidimensional prognostic indexIncreased riskfrailty; multidimensional prognostic index; prognosis; mortalityMedicineFemaleIndependent LivingprognosisOlder peoplebusinessInternational Journal of Environmental Research and Public Health; Volume 18; Issue 23; Pages: 12435
researchProduct

Very preterm birth: who has access to antenatal corticosteroid therapy?

2010

International audience; We describe the administration of antenatal corticosteroid therapy (ACT) for liveborn very preterm neonates in a population-based study. A total of 790 very preterm neonates (between 24 and 31 full weeks of gestation) were included in this regionally defined population of very preterm neonates in France. The main outcome measure was non-access to ACT. Data were analysed using logistic and polytomous models to control for neonatal and sociodemographic characteristics, mechanisms of very preterm birth and neonatal network organisation. As compared with level III, births in levels I-II maternity units were closely related to non-access to ACT (60.1% vs. 8.8%), but not t…

Gestational hypertensionPediatricsEpidemiologyMESH: Logistic ModelsHealth Services AccessibilityInfant Newborn Diseases[ SDV.CAN ] Life Sciences [q-bio]/CancerCohort Studies0302 clinical medicineMESH: PregnancyMESH : Health Services AccessibilityMESH: Risk FactorsAdrenal Cortex HormonesPregnancyRisk FactorsMESH: Maternal Health ServicesMESH : Socioeconomic FactorsMedicineChildbirthRupture of membranesMESH : FemaleMESH: Cohort StudiesMESH : Infant Newborn Diseaseseducation.field_of_studyMESH: Health Services Accessibility030219 obstetrics & reproductive medicineMESH: Middle AgedObstetricsMESH: Infant NewbornSmokingAge FactorsMiddle AgedMESH : AdultMESH : Risk Factors3. Good healthMESH : SmokingMESH : Infant PrematureMESH: Young AdultGestationFemaleFranceInfant PrematureMESH: Infant PrematureAdultmedicine.medical_specialtyMESH: SmokingMESH: Socioeconomic FactorsReferralAdolescentPopulationMESH : Young AdultMESH : Cohort StudiesMESH: Infant Newborn Diseases[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Infant NewbornMESH: Adrenal Cortex HormonesMESH : Adrenal Cortex Hormones03 medical and health sciencesYoung Adult030225 pediatricsMESH : AdolescentVery Preterm BirthHumansMaternal Health ServicesMESH : Middle AgededucationMESH : FranceMESH: AdolescentMESH: Age FactorsPregnancyMESH: Humansbusiness.industryMESH : HumansInfant NewbornMESH: Adultmedicine.diseaseMESH: FranceMESH : PregnancyLogistic ModelsSocioeconomic FactorsPediatrics Perinatology and Child HealthMESH : Age FactorsbusinessMESH: FemaleMESH : Maternal Health ServicesMESH : Logistic Models
researchProduct

Real-world evidence from a European cohort study of patients with treatment resistant depression:Healthcare resource utilization

2022

Journal of affective disorders 298, Part A 442-450 (2022). doi:10.1016/j.jad.2021.11.004 special issue: "Special Issue on Corona Virus / Edited by Allan Young, Ron Acierno, Xiang Yang Zhang"

Healthcare resource utilization Major depressive disorder Observational study Real-world evidence Treatment resistant depressionmedicine.medical_specialtyMajor depressive disorderTreatment resistant depressionCohort StudiesIndirect costsDepressive Disorder Treatment-ResistantHealthcare resource utilization; Major depressive disorder; Observational study; Real-world evidence; Treatment resistant depressionObservational studyHealth careHealthcare resource utilizationmedicineHumansMajor depressive episodeDepression (differential diagnoses)Retrospective StudiesReal-world evidenceDepressive DisorderDepressive Disorder Majorbusiness.industryTreatment-ResistantMajorHealth Care Costsmedicine.diseasePsychiatry and Mental healthClinical PsychologyEmergency medicineMajor depressive disorderObservational studymedicine.symptombusinessHealthcare resource utilization; Major depressive disorder; Observational study; Real-world evidence; Treatment resistant depression; Cohort Studies; Delivery of Health Care; Health Care Costs; Humans; Retrospective Studies; Depressive Disorder Major; Depressive Disorder Treatment-ResistantTreatment-resistant depressionDelivery of Health CareCohort study
researchProduct

Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model

2022

Purpose We aimed to evaluate the near-final height (nFHt) in a large cohort of pediatricpatients with growth hormone deficiency (GHD) and to elaborate a new predictive method of nFHt. Methods We recruited GHD patients diagnosed between 1987 and 2014 and followed-up until nFHt. To predict the values of nFHt, each predictor was run in a univariable spline. Results We enrolled 1051 patients. Pre-treatment height was -2.43 SDS, lower than parental height (THt) (-1.09 SDS, p < 0.001). The dose of recombinant human GH (rhGH) was 0.21mg/kg/week at start of treatment. nFHt was -1.08 SDS (height gain 1.27 SDS), higher than pre-treatment height (p < 0.001) and comparable to THt. 1.6% of the pat…

Insulin-like growth factor 1Human Growth HormoneEndocrinology Diabetes and MetabolismPubertyFinal height; Growth; Growth hormone deficiency; Growth hormone retesting; Insulin-like growth factor 1; LMG method; PredictionDwarfismGrowthBody HeightCohort StudiesEndocrinologySettore MED/38 - Pediatria Generale E SpecialisticaGrowth hormone retestingPituitaryFinal heightGrowth HormoneFinal height; Growth; Growth hormone deficiency; Growth hormone retesting; Insulin-like growth factor 1; LMG method; Prediction; Body Height; Child; Cohort Studies; Growth Hormone; Humans; Puberty; Dwarfism Pituitary; Human Growth HormoneHumansGrowth hormone deficiencyLMG methodDwarfism PituitaryPredictionChildFinal height Growth Growth hormone deficiency Growth hormone retesting Insulin-like growth factor 1 LMG method Prediction
researchProduct

The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design

2017

Dementia with Lewy bodies (DLB) causes elevated outlays for the National Health Systems due to high institutionalization rate and patients' reduced quality of life and high mortality. Furthermore, DLB is often misdiagnosed as Alzheimer's disease. These data motivate harmonized multicenter longitudinal cohort studies to improve clinical management and therapy monitoring. The Italian DLB study group of the Italian Neurological Society for dementia (SINdem) developed and emailed a semi-structured questionnaire to 572 national dementia centers (from primary to tertiary) to prepare an Italian large longitudinal cohort. The questionnaire surveyed: (1) prevalence and incidence of DLB; (2) clinical…

Lewy Body Diseasemedicine.medical_specialtyPediatricsDementia with Lewy bodieDementia with Lewy bodiesDermatologyCohort StudiesDiagnosis Differential03 medical and health sciences0302 clinical medicineQuality of lifeAlzheimer DiseaseSurveys and Questionnairesmental disordersStandardization of diagnostic proceduresDiagnosisDementia with Lewy bodies; Standardization of diagnostic procedures; Survey; Alzheimer Disease; Cohort Studies; Diagnosis Differential; Disease Management; Humans; Italy; Lewy Body Disease; Research Design; Surveys and Questionnaires; 2708; Neurology (clinical); Psychiatry and Mental HealthmedicineDementiaHumans030212 general & internal medicineSurveyMED/01 - STATISTICA MEDICAMED/26 - NEUROLOGIAbusiness.industryDementia with Lewy bodiesDisease ManagementStandardization of diagnostic procedureGeneral Medicinemedicine.diseaseSettore MED/26 - NEUROLOGIADementia with Lewy bodies; Standardization of diagnostic procedures; Survey; 2708; Neurology (clinical); Psychiatry and Mental HealthItalyResearch DesignPsychiatry and Mental HealthCohortDifferentialPhysical therapyDeliriumNeurology (clinical)Alzheimer's diseasemedicine.symptombusiness030217 neurology & neurosurgeryFrontotemporal dementiaCohort study2708
researchProduct